1[1]Tandon R,Milner K,Jibson MD.Antipsychotics from theory to practice:integrating clinical and basic data[J].J Clin Psychiatry,1999,60(Suppl 8)∶S21-S28.
2[2]Geddes J,Freemantle N,Harrison P,et al.Atypical antipsychotics in the treatment of schizophrenia:systematic overview and meta regression analysis[J].Br Med J,2000,321∶1371-2000.
3[3]Chakos M,Lieberman J,Hoffman E,et al.Effectiveness of second-generation antipsychotics in treatment-resistant schizophrenia:a review and meta-analysis of randomized trials[J].Am J Psychiatry,2001,158(4)∶518-526.
4[4]Kent J.SNaRIs,NaSSAs,NaRIS:new drugs for treating depression[J].Lancet,2000,355∶911-918.
5[5]Freemantle N,Anderson I,Young P.Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs:meta-regression analysis[J].Br J Psychiatry,2000,177∶292-302.
6[2]Small JG, Hirsch SR, Arvantis LA, et al. Quetiapine in patients with schizophrenia. A high and Low - dose - double - blind comparison with placebo. Arch Gen Psychiatry, 1997, 54(6) : 549
7[3]Widen P, Mcelrop SL, Griffin RA, et al. Quetiapine in the treatment resistant chronic schizophrenia: a randomized double-blind study. J Clin Psychiatry, 1997, 58(3) : 63
8[4]Arvanitis LA, Kandel ER. Quetiapine in the treatment of schizophrenia patient. Biol Psychiatry, 1997,42(4) : 233
